Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > STAT3


Brief Information

Name:Signal transducer and activator of transcription 3
Target Synonym:Acute-phase response factor,APRF,STAT3,Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor),Signal transducer and activator of transcription 3,DNA-Binding Protein APRF,ADMIO1,ADMIO,HIES,STAT3 Transcription Factor
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ST3-H5149 Human Human STAT3 Protein, His Tag (MALS & SPR verified)
CHEK-ATF047 Human STAT3 (Luc) HEK293 Reporter Cell
ACRO Quality

Part of Bioactivity data


Human STAT3, His Tag (Cat. No. ST3-H5149) immobilized on CM5 Chip can bind STAT3 degrader with an affinity constant of 44.6 nM as determined in a SPR assay (Biacore 8K) (QC tested).


Loaded Human STAT3, His Tag (Cat. No. ST3-H5149) on NTA Biosensor, can bind STAT3 degrader with an affinity constant of 29.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

STAT3, signal transducer and activator of transcription 3


Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes important for essential cellular processes including survival, proliferation, self-renewal, angiogenesis, and immune response. As an early tumor diagnostic marker, it is considered that constitutive STAT3 activation is a sufficient factor to cause malignant transformation and tumor development in model systems. The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Caffeic Acid CABE Approved The University Of Texas MD Anderson Cancer Center, Moleculin Llc Hemorrhage; Leukopenia; Thrombocytopenia Details
Golotimod SCV-07 Approved Verta Russian Federation Hepatitis C; Mucositis null 2009-01-01 Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OPB-111077 OPB-111077 Phase 2 Clinical Otsuka Pharmaceutical Co Ltd Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular Details
Dimethylaminomicheliolide Fumarate ACT-001 Phase 2 Clinical Tianjin Accendatech Technology Co Ltd Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
[14C]ACT-001 [14C]ACT001 Phase 1 Clinical Tianjin Xinyi Shangde Biomedical Technology Co Ltd Solid tumours Details
Napabucasin DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) Phase 3 Clinical 1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
NT-219 NT-219; NT219 Phase 2 Clinical TyrNovo Ltd Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis Details
Nanocurcumin (Tehran University of Medical Sciences) Clinical Tehran University Of Medical Sciences Neoplasms Details
OPB-171775 OPB-171775 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd Non-alcoholic Fatty Liver Disease Details
VVD-130850 VVD-130850 Vividion Therapeutics Inc Details
PCUR-101 PCUR-101 Phase 1 Clinical Pellficure Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
GLG-302 GLG-302; GLG-805; S31-201; NSC-74859 Phase 1 Clinical H Lee Moffitt Cancer Center & Research Institute Breast Neoplasms Details
DCR-STAT3 DCR-STAT3 Phase 1 Clinical Dicerna Pharmaceuticals Inc Solid tumours; Neoplasms Details
Danvatirsen AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx Phase 2 Clinical Ionis Pharmaceuticals Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
C-188-9 C188-9; C-188-9; TTI-101 Phase 2 Clinical Baylor College Of Medicine, Tvardi Therapeutics Inc Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
M-1001 M-1001; MEDICA-M1001 Phase 2 Clinical Syndromex Dyslipidemias Details
HL-237 HL-237 Phase 2 Clinical Hanlim Pharmaceutical Co Ltd Arthritis, Rheumatoid Details
Amcasertib/Napabucasin Phase 1 Clinical Boston Biomedical Inc Neoplasms Details
WP-1066 WP-1066 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma Details
MOL-4239 MOL-4239; WP-1220 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides Details
KT-333 KT-333; I-003 Phase 1 Clinical Kymera Therapeutics Inc Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
YY-201 YY201; YY-201 Phase 1 Clinical Yuyu Pharma Solid tumours; Hematologic Neoplasms; Prostatic Hyperplasia Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message